LifeStance Health Group, Inc. (LFST) Stock: Price, Forecast & Analyst Target
LifeStance Health Group, Inc. (LFST) — MoonshotScore 93/100 (Exceptional band), calculated Oct 5, 2026. Price $12.22 (+3.30%), as of the Oct 5, 2026 trading session; market cap $4.74B. Expected results Nov 5, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 20.98× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 5, 2026
LifeStance Health Group, Inc. · LFST · NASDAQ · Healthcare · Medical - Care Facilities
Research dated 2026-09-13: LifeStance delivers outpatient mental healthcare through a network of virtual and in-person centers across multiple states. The question is whether the business can scale profitable care delivery while managing reimbursement pressure and competition from larger healthcare systems.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · LifeStance Health Group (LFST)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Solid; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $435M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- Altman Z 4.31 · Piotroski F 8
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional |
The score was 93 in the stored Oct 4, 2026 snapshot and remains 93 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability -1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.22 | |
| Change on the day | +3.30% | |
| 52-week range | $4.77–$13.56 | |
| Market capitalisation | $4.74B | |
| Price / earnings (trailing) | 90.86 | |
| Shares traded on the day | 3.23M | |
| Beta (volatility vs the S&P 500) | 1.22 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
In terms of our outlook for the full year, we are raising our revenue range by $45 million at the midpoint to $1.685 billion to $1.725 billion.
Ryan McGroarty · Statement from
For the third quarter, we expect revenue of $420 million to $440 million, Center Margin of $140 million to $152 million and adjusted EBITDA of $49 million to $59 million.
Ryan McGroarty · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for LifeStance Health Group (LFST): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the LFST film — every key number, told as a short cinematic story
~2 min · open the film
What is LifeStance Health Group (LFST), and what does it report?
Short answer · as of
LifeStance offers psychiatric evaluations, psychological testing, therapy (individual, family, group), and treatment across a spectrum of mental health conditions.
Research dated 2026-09-13.
LifeStance offers psychiatric evaluations, psychological testing, therapy (individual, family, group), and treatment across a spectrum of mental health conditions. Patients access care virtually or at physical locations in states across the country. The business serves children, adolescents, adults, and the elderly. Revenue comes from insurance reimbursements, patient copays, and employer contracts for employee mental health benefits. The income statement shows improving margins as the company scales and achieves better payor mix and operational leverage.
The operating model is capital-light compared to traditional brick-and-mortar mental health centers. Virtual delivery reduces facility costs while maintaining quality of care.
What do the latest results show for LifeStance Health Group (LFST)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $435M.
Research dated 2026-09-13.
The most recent quarter showed improved profitability and earnings that beat analyst expectations, while revenue also came in ahead of estimates. This suggests the company is moving toward sustainable unit economics and scale. The gross margin expanded, driven by better payor mix and operational efficiency as patient volumes grow.
Management commentary emphasizes revenue growth and path to profitability. The company guides to accelerating earnings in subsequent periods, suggesting confidence in both volume growth and margin expansion.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $435.35M Jun 30, 2026
- Latest quarter · SG&A
- $108.14M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $30.65M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $435.35M | Not available | $108.14M | $30.65M |
| Mar 31, 2026 | $403.48M | Not available | $100.33M | $22.28M |
| Dec 31, 2025 | $382.19M | Not available | $94.78M | $18.08M |
| Sep 30, 2025 | $363.81M | Not available | $95.61M | $7.41M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $435.35M Aug 6, 2026
- Latest report · revenue estimate
- $414.58M Aug 6, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 6, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | $435.35M | $414.58M | $0.0600 | $0.0328 |
| May 7, 2026 | $403.50M | $387.46M | $0.0400 | $0.0100 |
| Feb 25, 2026 | $382.20M | $378.42M | $0.0300 | −$0.0009 |
| Nov 6, 2025 | $363.81M | $378.51M | $0.0028 | −$0.0100 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $435M | $24M | $0.06 (diluted) |
| Q1 FY2026 | $403M | $14M | $0.04 (diluted) |
| Q4 FY2025 | $382M | $12M | $0.03 (diluted) |
| Q3 FY2025 | $364M | $1M | $0.00 (diluted) |
What are the financial strengths and risks for LifeStance Health Group (LFST)?
Short answer
Cash and short-term investments were $225.94M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $99.91M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The company has a strong balance sheet with modest debt and a quick ratio above unity, indicating no near-term liquidity pressure. Operating cash generation is positive and robust, exceeding capital needs. The Altman score shows healthy distance from distress. Return on assets and return on equity are improving, reflecting the path to sustained profitability.
The main financial risk is reimbursement pressure from payors, which could squeeze margins if the company cannot offset with volume or operational improvement. Competitive intensity from larger healthcare systems entering mental health could also pressure pricing power.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $99.91M Jun 30, 2026
- Previous quarter · operating cash flow
- $33.11M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $99.91M | −$11.99M |
| Mar 31, 2026 | $33.11M | −$10.77M |
| Dec 31, 2025 | $57.56M | $25.21M |
| Sep 30, 2025 | $27.29M | −$10.29M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at LifeStance Health Group (LFST)?
Short answer · as of
The next earnings report is expected on Nov 5, 2026.
Research dated 2026-09-13.
The next earnings will show whether revenue growth continues and whether margins stabilize at the new higher level. Watch for any commentary on payor mix shifts, changes in reimbursement rates, or competitive pressures. Also monitor patient satisfaction metrics and retention, as these drive long-term sustainability.
The company's ability to expand into new states and verticals while maintaining profitability will determine whether the growth story continues. Any significant setback in payor negotiations or patient acquisition would pressure the valuation.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
In terms of our outlook for the full year, we are raising our revenue range by $45 million at the midpoint to $1.685 billion to $1.725 billion.
Ryan McGroarty ·
For the third quarter, we expect revenue of $420 million to $440 million, Center Margin of $140 million to $152 million and adjusted EBITDA of $49 million to $59 million.
Ryan McGroarty ·
How does LifeStance Health Group compare with its peers?
Short answer
LifeStance Health Group's score ranks tied for 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
LifeStance differs from traditional mental health providers in that it emphasizes virtual delivery and broad geographic reach, reducing geographic arbitrage and enabling rapid expansion. It differs from pure-play behavioral health startups in that it maintains physical centers as well, giving patients choice and broadening addressable market.
The competitive field includes large healthcare systems, telehealth platforms, and specialized behavioral health pure-plays. LifeStance's positioning as a hybrid (virtual + physical) with institutional backing differentiates it.
| Company | Price | Market value | Score |
|---|---|---|---|
| $230.37 Oct 5, 2026 | $3.60B | 98 5-pillar Oct 5, 2026 | |
| $176.05 Oct 5, 2026 | $10.7B | 94 5-pillar Oct 5, 2026 | |
| LifeStance Health Group (LFST) — this page | $12.22 | $4.74B | 93 |
| $112.98 Oct 5, 2026 | $2.11B | 93 5-pillar Oct 5, 2026 | |
| $26.10 Oct 5, 2026 | $2.13B | 90 5-pillar Oct 5, 2026 | |
| $120.97 Oct 5, 2026 | $12.0B | 90 5-pillar Oct 5, 2026 | |
| $511.30 Oct 5, 2026 | $6.63B | 87 5-pillar Oct 5, 2026 | |
| $22.65 Oct 5, 2026 | $12.0B | 83 5-pillar Oct 5, 2026 | |
| $23.37 Oct 5, 2026 | $3.50B | 81 5-pillar Oct 5, 2026 | |
| $12.37 Oct 5, 2026 | $2.68B | 81 5-pillar Oct 5, 2026 | |
| $172.89 Oct 5, 2026 | $10.1B | 75 5-pillar Oct 5, 2026 | |
| $178.72 Oct 5, 2026 | $11.5B | 75 5-pillar Oct 5, 2026 | |
| $36.81 Oct 5, 2026 | $1.83B | 74 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $9.00 – $19.00
- Consensus target
- $13.86
- Median target
- $13.00
Consensus record · Captured .
Measured against a quoted price of $12.22 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 22, 2026
- Transactions
- 36
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 23
- Other transactions
- 13
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 98.5% Period end Jun 30, 2026
- Previous quarter · ownership
- 95.2% Prior to period end Jun 30, 2026
- Reporting holders
- 297 Period end Jun 30, 2026
- Previous quarter · holders
- 232 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Tpg Gp A, LLC | 111,744,614 |
| Fmr LLC | 58,252,466 |
| Blackrock, INC. | 36,348,507 |
| Summit Partners L P | 23,310,115 |
| Vanguard Portfolio Management LLC | 13,960,892 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about LifeStance Health Group (LFST)?
- LifeStance Health CTO Sells 42,067 Shares for $541,402
- LifeStance Health Group (LFST): Buy, Sell, or Hold Post Q2 Earnings?
- LifeStance Health Group (NASDAQ:LFST): Strongest Q2 Results from the Outpatient & Specialty Care Group
- 74,169 Shares in LifeStance Health Group, Inc. $LFST Bought by HighTower Advisors LLC
LifeStance Health Group Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is the business model for mental health delivery?
LifeStance contracts with insurance companies and employers for mental health services. Patients pay copays; payers reimburse the company. The company manages clinician networks (employed or contracted) and coordinates care delivery. Revenue grows as patient volume and contract value expand; margins expand as operational scale improves. The model requires scale to be profitable, as fixed costs for infrastructure and administration are high relative to marginal cost per patient visit.
What are the main risks to the margin expansion story?
Payor reimbursement rates could fall, squeezing gross margins. Clinician wages could rise faster than reimbursement, compressing operating margins. Competitive intensity from larger health systems entering the market could pressure pricing and patient acquisition costs. Regulatory changes in licensing, telehealth coverage, or insurance policy could shift the addressable market or cost structure unexpectedly.
Is management buying or selling shares?
Recent insider activity shows significant sales by company insiders, concentrated around certain price levels and dates. The sellers are CFOs, founders, and executives, which could signal either profit-taking or concern about near-term prospects. The scale of selling relative to institutional ownership is material enough to warrant monitoring but not so extreme as to suggest a crisis of confidence.
How does LifeStance compare to larger healthcare systems entering mental health?
Larger systems (Humana, CVS, United Health) have vast scale, integrated insurance and care, and established payor relationships. LifeStance has specialized focus, lower cost structure, and agility. Neither has inherent superiority; market share will likely be split by geography and payor preference. LifeStance's advantage is that mental health is a small segment of large systems' business, so they may under-invest while LifeStance keeps innovating.
What is the LFST stock price today?
The last price recorded on this page for LifeStance Health Group, Inc. (LFST) is $12.22, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LFST price target?
The analyst consensus price target for LifeStance Health Group, Inc. (LFST) is $13.86 (range $9.00 to $19.00, median $13.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (78 figures)
The 78 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Ryan McGroarty (Aug 6, 2026): In terms of our outlook for the full year, we are raising our revenue range by $45 million at the midpoint to $1.685 billion to $1.725 billion. Ryan McGroarty (Aug 6, 2026): For the third quarter, we expect revenue of $420 million to $440 million, Center Margin of $140 million to $152 million and adjusted EBITDA of $49 million to $59 million. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 4800 N. Scottsdale Road, Suite 2500, Scottsdale, AZ, 85251 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "4800 N. Scottsdale Road, Scottsdale, AZ, 85251, US". |
FMP — 69 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 5, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $12.22 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:55:04.746Z. | |
px.change | Change on the day | +3.30% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $4.74B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:01.000Z. Captured from FMP at 2026-10-05T21:55:03.510Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.39 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $435M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $4.77–$13.56 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 90.86 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.23M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.22 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | David Patrick Bourdon | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 8,542 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $667.51M, net result −$307.20M; FY2022 revenue $859.54M, net result −$215.56M; FY2023 revenue $1.06B, net result −$186.26M; FY2024 revenue $1.25B, net result −$57.44M; FY2025 revenue $1.42B, net result $9.66M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 33.6% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $435.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $108.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $30.65M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $403.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $100.33M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $22.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $382.19M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $94.78M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $18.08M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $363.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $95.61M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $7.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.revenue_actual | Revenue · reported — report date 2026-08-06 | $435.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $414.58M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | $0.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | $0.0328 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $403.50M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $387.46M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | $0.0400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | $0.0100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.revenue_actual | Revenue · reported — report date 2026-02-25 | $382.20M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.revenue_estimated | Revenue · estimate — report date 2026-02-25 | $378.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.eps_actual | EPS · reported — report date 2026-02-25 | $0.0300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.eps_estimated | EPS · estimate — report date 2026-02-25 | −$0.0009 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_actual | Revenue · reported — report date 2025-11-06 | $363.81M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_estimated | Revenue · estimate — report date 2025-11-06 | $378.51M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_actual | EPS · reported — report date 2025-11-06 | $0.0028 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_estimated | EPS · estimate — report date 2025-11-06 | −$0.0100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $225.94M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $99.91M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $200.66M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.07× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $99.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $33.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$11.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$10.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $57.56M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | $25.21M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $27.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$10.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $9.00 – $19.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $13.86 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $13.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 36 transactions · 0 purchases, 23 sales, 13 other transactions · 14 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 22, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 98.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 95.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 297 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 232 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Tpg Gp A, LLC — shares in provider snapshot | 111,744,614 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Fmr LLC — shares in provider snapshot | 58,252,466 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 36,348,507 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Summit Partners L P — shares in provider snapshot | 23,310,115 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 13,960,892 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-16 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 4.31 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 20.98× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $225.94M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-06.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($435.35M) with the recorded estimate ($414.58M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.0600) with the recorded estimate ($0.0328) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 93 of 100 · Exceptional · pillars 76 / 80 / 59 / 97 / 93 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 93 (stored snapshot Oct 4, 2026) → 93 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_actual,earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.revenue_actual.comparison,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-25.revenue_actual,earn.history.depth.2026-02-25.revenue_estimated,earn.history.depth.2026-02-25.eps_actual,earn.history.depth.2026-02-25.eps_estimated,earn.history.depth.2025-11-06.revenue_actual,earn.history.depth.2025-11-06.revenue_estimated,earn.history.depth.2025-11-06.eps_actual,earn.history.depth.2025-11-06.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | LifeStance Health Group, Inc. specializes in delivering outpatient mental healthcare services through its subsidiary network. The company offers a comprehensive array of mental health solutions, encompassing psychiatric evaluations and treatment, specialized psychological and neuropsychological testing, and diverse therapeutic modalities including individual, family, and group therapy sessions. The organization addresses a wide spectrum of mental health conditions, ranging from common issues like anxiety and depression to more complex challenges such as bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. Patients have access to care through various channels: virtually via its online platform or in-person at its many centers located throughout 32 states. LifeStance is dedicated to supporting individuals across all age groups, providing care for children, adolescents, adults, and the elderly. LifeStance Health Group, Inc. was founded in 2017 and its main offices are situated in Scottsdale, Arizona. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Care Facilities The company's SEC filings classify it under SIC 8000 — Services-Health Services. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-06 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $200.66M; Liquidity basis: cash and short-term investments; Total liabilities: $704.35M; Cash and short-term investments: $225.94M; Cash and investments: $225.90M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Trailing twelve-month ratio set | Quick ratio: 1.38; Current ratio: 1.38; Debt to equity: 0.14; Net margin: 3.2%; Gross margin: 33.6%; Operating margin: 4.9%; Return on assets: 2.3%; Return on equity: 3.4% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-11-05; EPS estimate: $0.03 per share; Revenue estimate: $431.36M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Analyst actions, most recent per firm | Captured record · 10 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-09-10 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Insider transactions, last 180 days | Net shares: -50,419,232; Window days: 180; Price low: $6.37; Clustered days: 2026-05-12; 2026-07-02; 2026-08-10; Price high: $12.87; Buy transactions: 0; Distinct insiders: 16; Sell transactions: 22; Other transactions: 13; Total transactions: 35; Other transaction types: A-Award: 7, J-Other: 1, F-InKind: 5; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-02 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Institutional ownership (13F) | Holders: 297; Quarter: 2026-06-30; Ownership: 98.5%; Holders previous quarter: 232; Ownership previous quarter: 95.2 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Named officers | CEO: David Patrick Bourdon; Officers: Vukasin Paunovich — Title: Chief Technology Officer, Pay: $644,201, Born: 1972; Lisa Keise Miller — Title: Chief Operating Officer & Principal Operating Officer, Born: 1974; Monica Prokocki — Title: Vice President of Investor Relations; Brooke Matthews — Title: Director of Public Relations; David Patrick Bourdon — Title: Chief Executive Officer & Director, Pay: $1.39M, Born: 1969; Richard Hall — Title: Chief Shared Services Officer; Ryan Bruce McGroarty — Title: Chief Financial Officer & Treasurer, Pay: $1.52M, Born: 1973; Kenneth Alan Burdick — Title: Executive Chairman, Pay: $650,154, Born: 1959 Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
Data provided for informational purposes only.